NOT FOR DISTRIBUTION IN THE UNITED STATES (OR TO US CITIZENS), THE UNITED KINGDOM AND THE EEA.

mondoBIOTECH holding AG announces today the global terms of a share capital increase structured as a rights offering to existing shareholders (the "Rights Offering"), with shares not taken up in the Rights Offering to be placed privately by the Company with selected investors (the "Selected Offering", and together with the Rights Offering, the "Offering").

mondoBIOTECH holding AG (SIX: RARE) newly appointed Head of Business Development & Licensing Dr. David Cox will present at the upcoming Bio-Europe Spring conference being held in Milan Italy. The presentation will take place on Wednesday March 16 at 9.15am.

mondoBIOTECH holding AG (SIX: RARE) announces today that the United States FDA has granted mondoBIOTECH the Orphan Drug Designation for the treatment of the rare disease Sarcoidosis to its medicinal product candidate, the human peptide Thymopentin (FDA n. 10/3300).